The first reports of the cost-effectiveness evaluation were released.

Reports of the cost-effectiveness evaluation on Fluticasone/Umeclidinium/Vilanterol (Trelegy) and Tisagenlecleucel (Kymriah) were released. These are our first reports since this HTA system was started from April 2019 in Japan.